Temozolomide in combination with interferon α-2b in patients with metastatic melanoma: A Phase I dose-escalation study

Cancer

Volumn 97, Issue 1, 2003, Pages 121-127

  Agarwala, Sanjiv S ^a   Kirkwood, John M ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Central nervous system recurrence; Interferon 2b; Metastatic melanoma; Temozolomide

Indexed keywords

ALPHA2B INTERFERON; TEMOZOLOMIDE;

ADULT; AGED; ANXIETY; ARTICLE; BRAIN METASTASIS; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE CALCULATION; DRUG ACTIVITY; DRUG RESPONSE; DRUG SAFETY; FATIGUE; FEMALE; FEVER; HUMAN; INCIDENCE; MALE; MELANOMA; METASTASIS; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; TIME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DACARBAZINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTERFERON ALFA-2B; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; NEUTROPENIA; SKIN NEOPLASMS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0037217219     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11041     Document Type: Article

References (36)

1. Balch CM, Reintgen DS, Kirkwood JM, Houghton A, Peters L, Ang KK. Cutaneous melanoma. In: DeVita VT Jr., Hellman S, Rosenberg SA, editors. Cancer: Principles and Practice of Oncology, 5th Edition. Philadelphia: Lippincott-Raven, 1997: 1947-1994.
2. Ramirez G, Wilson W, Grage T, Hill G. Phase II evaluation of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962) in patients with solid tumors. Cancer Chemother Rep. 1972; 56:787-790.
3. Ahmann DL, Hahn RG, Bisel HF. A comparative study of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (NSC 79037) and imidazole carboxamide (NSC 45388) with vincristine (NSC 67574) in the palliation of disseminated malignant melanoma. Cancer Res. 1972;32:2432-2434.
4. Al-Sarraf M, Fletcher W, Oishi N, et al. Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: A Southwest Oncology Group study. Cancer Treat Rep. 1982;66:31-35.
5. Evans LM, Casper ES, Rosenbluth R. Phase II trial of carboplatin in advanced malignant melanoma. Cancer Treat Rep. 1987;71:171-172.
6. Saxman SB, Meyers ML, Chapman PB, et al. A Phase III multicenter randomized trial of DTIC, cisplatin, BCNU and tamoxifen versus DTIC alone in patients with metastatic melanoma [abstract 2068]. Proc Am Soc Clin Oncol. 1999;18: 536a.
7. Kirkwood JM, Agarwala SS. Systemic cytotoxic and biologic therapy of melanoma (PPO updates). In: DeVita VT Jr., Hellman S, Rosenberg SA, editors. Cancer: Principles and Practice of Oncology. Volume 7, 4th Edition. Philadelphia,: JB Lippincott Company, 1993.
8. Legha SS, Ring S, Papadopoulos N, Plager C, Chawla S, Benjamin R. A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. Cancer. 1989;64:2024-2029.
9. Seigler HF, Lucas VS Jr., Pickett NJ, Huang AT. DTIC, CCNU, bleomycin and vincristine (BOLD) in metastatic melanoma. Cancer. 1980;46:2346-2348.
10. Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA. 1994;271: 907-913.
11. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17:2105-2116.
12. Legha SS. The role of interferon alfa in the treatment of metastatic melanoma. Semin Oncol. 1997(Suppl 4);24:S24-S31.
13. Khayat D, Borel C, Tourani JM, et al. Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma. J Clin Oncol. 1993;11: 2173-2180.
14. Keilholz U, Goey SH, Punt CJ, et al. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: A randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol. 1997;15:2579-2588.
15. Legha SS, Ring S, Bedikian A, et al. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. Ann Oncol. 1996;7: 827-835.
16. Legha SS, Ring S, Eton O, et al. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol. 1998;16:1752-1759.
17. Richards JM, Mehta N, Ramming K, Skosey P. Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol. 1992;10:1338-1343.
18. Richards JM, Gale D, Mehta N, Lestingi T. Combination of chemotherapy with interleukin-2 and interferon alfa for the treatment of metastatic melanoma. J Clin Oncol. 1999;17: 651-657.
19. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol. 1999;17: 968-975.
20. McDermott DF, Mier JW, Lawrence DP, et al. A Phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma. Clin Cancer Res. 2000; 6:2201-2208.
21. Atkins MB, Gollob JA, Mier JW, et al. Phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide (CVT), interleukin-2 (IL-2) and interferon α-2b (IFN) in patients with metastatic melanoma [abstract 1391]. Proc Am Soc Clin Oncol. 2001;20:349a.
22. Summers Y, Middleton MR, Calvert H, et al. Effect of temozolomide (TMZ) on central nervous system (CNS) relapse in patients with advanced melanoma [abstract 2048]. Proc Am Soc Clin Oncol. 1999;18:531a.
23. Newlands ES, Blackledge GR, Slack JA, et al. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer. 1992;65:287-291.
24. Bleehen NM, Newlands ES, Lee SM, et al. Cancer Research Campaign Phase II trial of temozolomide in metastatic melanoma. J Clin Oncol. 1995;13:910-913.
25. 6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma. Br J Cancer. 1998;78:1199-1202.
26. Middleton MR, Grob JJ, Aaronson N, et al. Randomized Phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000;18:158-166.
27. Jen JF, Cutler DL, Pai SM, et al. Population pharmacokinetics of temozolomide in cancer patients. Pharm Res. 2000;17: 1284-1289.
28. Stupp R, Ostermann S, Leyvraz S, Csajka C, Buclin T, Decosterd LA. Cerebrospinal fluid levels of temozolomide as a surrogate marker for brain penetration [abstract]. Proc Am Soc Clin Oncol. 2001;20:59a.
29. Agarwala SS, Reyderman L, Statkevich P, et al. Pharmacokinetic study of temozolomide penetration into CSF in a patient with dural melanoma [abstract]. Ann Oncol. 1998;9: 138.
30. Brada M, Judson I, Beale P, et al. Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. Br J Cancer. 1999;81: 1022-1030.
31. Hammond LA, Eckardt JR, Baker SD, et al. Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies. J Clin Oncol. 1999;17:2604-2613.
32. Brock CS, Newlands ES, Wedge SR, et al. Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res. 1998;58:4363-4367.
33. Dhodapkar M, Rubin J, Reid JM, et al. Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer. Clin Cancer Res. 1997;3:1093-1100.
34. Newlands ES, Stevens MFG, Wedge SR, Wheelhouse RT, Brock C. Temozolomide: A review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev. 1997;23:35-61.
35. Patel JK, Didolkar MS, Pickren JW, Moore RH. Metastatic pattern of malignant melanoma. A study of 216 autopsy cases. Am J Surg. 1978;135:807-810.
36. Bafaloukos D, Gogas H, Georgoulias V, et al. Temozolomide in combination with docetaxel in patients with advanced melanoma: A Phase II study of the Hellenic Cooperative Oncology Group. J Clin Oncol. 2002;20:420-425.